Skip to main
BBIO
BBIO logo

BBIO Stock Forecast & Price Target

BBIO Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 52%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Pharma has demonstrated strong commercial momentum, recording a notable increase in prescriptions for Attruby, with figures rising from 430 to 1,028 patient scripts, and an increase in unique prescribers from 248 to 516 within a short period, signifying robust early-stage demand. This demand is likely bolstered by the favorable mortality data from the phase 3 ATTRibute-CM trial, which has effectively showcased the drug's capabilities in reducing cardiovascular-related hospitalizations and improving patient outcomes. Furthermore, the potential for market expansion through increased awareness and diagnosis, coupled with the positive growth trajectory projected into 2026, supports a favorable long-term outlook for BridgeBio Pharma's stock performance.

Bears say

BridgeBio Pharma faces significant challenges that contribute to a negative outlook, including the lack of robust commercial infrastructure necessary to support the launch of its key product, acoramidis. The company encounters legislative pressures surrounding drug pricing in the U.S. and struggles to form meaningful partnerships or distribution agreements outside the U.S., which limits the potential value of its drug candidates. Furthermore, uncertainties surrounding funding sources and the risk of clinical trial data leading to negative results or delays further exacerbate the potential for medium- to long-term dilution of shareholder value.

BBIO has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 52% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Pharma Inc (BBIO) Forecast

Analysts have given BBIO a Buy based on their latest research and market trends.

According to 21 analysts, BBIO has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Pharma Inc (BBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.